Independent reference. Not affiliated with, endorsed by, or speaking for the U.S. Food and Drug Administration.

FDA Medication Tracker

Diagnostic & imaging agents: new FDA approvals

Brand, generic name, approval date and the use the FDA approved it for. No recommendations. Updated 2026-10-12.

Weight loss & diabetes Cancer Brain & mental health Infections & vaccines Heart & blood Immune & inflammatory Kidney, liver & lung Eye Women's & hormonal health Pain & anesthesia Diagnostic & imaging agents Rare & genetic Other

AmbelvistDiagnostic & imaging agents
June 12, 2026
gadoquatrane · Bayer Healthcare
To detect and visualize lesions with abnormal vascularity, in conjunction with MRI
IomervuDiagnostic & imaging agents
November 27, 2024
iomeprol · Bracco
For use as a radiographic contrast agent
LumisightDiagnostic & imaging agents
April 17, 2024
pegulicianine · Lumicell
To use as an optical imaging agent for the detection of cancerous tissue

Facts only. This site lists what the FDA has approved and what the FDA says each drug is approved for, quoted or closely paraphrased from FDA and openFDA records. It gives no medical advice, no dosing, and no comparisons, and it says nothing about whether a drug is right for anyone. Talk to a licensed clinician about any medication. Records can lag or contain errors; the FDA's own pages are authoritative.